A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
Status:
Withdrawn
Trial end date:
2024-02-23
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2 Simon 2-Stage study designed to assess the safety,
tolerability, PK, and efficacy of oral zelavespib (PU-H71) administered daily in adults with
accelerated phase (10% to 19% blasts in peripheral or bone marrow) myeloproliferative
neoplasm, with or without ongoing concomitant treatment with ruxolitinib.